Posts

Showing posts with the label Gene Therapy Market 2026

Gene Therapy Market Led To A Lucrative Growth At A CAGR Of 33.9% For The Forecast Period From 2019 To 2026 : Grand View Research Inc.

Image
San Francisco, 16 July 2019:   The Report   Gene Therapy Market   Size, Share & Trends Analysis Report By Vector (Lentivirus, RetroVirus & Gamma RetroVirus), By Indication (Beta-Thalassemia Major/SCD, ALL, Large B-cell Lymphoma), And Segment Forecasts, 2019 – 2026 The global gene therapy market size is expected to reach USD 5.55 billion by 2026, growing at a CAGR of 33.9% over the forecast period, according to a new report by Grand View Research, Inc. Gene therapy is being developed with an aim to identify and cure rare conditions, diseases that have limited treatment options and that need lifelong medication to keep the symptoms in check. For instance, metabolic disorders like lysosomal diseases need constant medical attention with the medication available now, however, gene therapy might become a one-time cure to such diseases. There are a number of molecules under development due to intense competition. This factor is projected to be the key factor propelling the mark

Gene Therapy Market To Witness A Significant Growth Rate In The Forecast Years from 2018-2026: Grand View Research Inc.

San Francisco, 25 February 2019: The Report GeneTherapy Market Size, Share & Trends Analysis Report By Indication (Cancer, Genetic Disorders, Infectious Diseases, CVD, Neuro Disorders), By Vector Type (Viral, Non-Viral), By Region, and Segment Forecasts, 2018 – 2026 The global gene therapy market size is expected to reach USD 39.54 million by 2026. Rising competition among manufacturers and high number of molecules in pipeline are supporting the growth of the market. Gene therapy development is aimed to cure rare diseases and even some hereditary diseases, which are caused by a mutated or faulty gene. Moreover, ever-increasing need for new cures for orphan diseases and rising incidence of cancer caused due to mutations in genes are likely to stir up the demand for gene therapy. As of early 2016, there were more than 1000 molecules in the pipeline in various clinical phases. However, around 76.0% of the molecules are in the developmental or preclinical stages and expecte